Determinants of protection among HIV-exposed seronegative persons: An overview

Journal of Infectious Diseases

Volumn 202, Issue SUPP.3, 2010, Pages

  Lederman, Michael M ^a   Alter, Galit ^d   Daskalakis, Demetre C ^e   Rodriguez, Benigno ^a   Sieg, Scott F ^a   Hardy, Gareth ^a   Cho, Michael ^f   Anthony, Donald ^a   Harding, Clifford ^a   Weinberg, Aaron ^b   Silverman, Robert H ^c   Douek, Daniel C ^g   Margolis, Leonid ^h   Goldstein, David B ^k   Carrington, Mary ^j   Goedert, James J ⁱ  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d HARVARD UNIVERSITY   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f IOWA STATE UNIVERSITY   (United States)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

^j NATIONAL INSTITUTES OF HEALTH   (United States)

^k DUKE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; HLA ANTIGEN CLASS 1; INITIATION FACTOR 2ALPHA; INTERFERON; RIBONUCLEASE L; VIRUS RECEPTOR;

ADAPTIVE IMMUNITY; BASE PAIRING; CD4+ T LYMPHOCYTE; CELL SURFACE; CONFERENCE PAPER; GENE EXPRESSION; GENE MUTATION; HEMOPHILIA; HEPATITIS C; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INNATE IMMUNITY; MIXED INFECTION; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN MOTIF; RISK FACTOR; SCREENING; SERODIAGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE ACTIVATION; VIRUS IMMUNITY; VIRUS INFECTIVITY; VIRUS RESISTANCE; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; REVIEW;

HIV; HIV INFECTIONS; HUMANS; IMMUNITY, INNATE; RECEPTORS, CCR5; RECEPTORS, HIV;

EID: 78049445926     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/655967     Document Type: Conference Paper

References (54)

1. Royce RA, Sena A, Cates W Jr, Cohen MS. Sexual transmission of HIV. N Engl J Med 1997; 336:1072-1078.
2. Cohen MS, Shugars DC, Fiscus SA. Limits on oral transmission of HIV-1. Lancet 2000; 356:272.
3. Martin MP, Lederman MM, Hutcheson HB, et al. Association of DC-SIGN promoter polymorphism with increased risk for parenteral, but not mucosal, acquisition of human immunodeficiency virus type 1 infection. J Virol 2004; 78:14053-14056.
4. Margolis L, Shattock R. Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved? Nat Rev Microbiol 2006; 4:312-317.
5. Smith SM, Baskin GB, Marx PA. Estrogen protects against vaginal transmission of simian immunodeficiency virus. J Infect Dis 2000; 182:708-715.
6. Kaul R, Rowland-Jones SL, Kimani J, et al. Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific CD8+ responses. J Clin Invest 2001; 107:341-349. (Pubitemid 32157966)
7. Hummel S, Schmidt D, Kremeyer B, Herrmann B, Oppermann M. Detection of the CCR5-delta32 HIV resistance gene in Bronze Age skeletons. Genes Immun 2005; 6:371-374.
8. Sabeti PC, Walsh E, Schaffner SF, et al. The case for selection at CCR5-delta32. PLoS Biol 2005; 3:e378.
9. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene: Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273:1856-1862.
10. Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996; 2:1240-1243.
11. Zimmerman PA, Buckler-White A, Alkhatib G, et al. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol Med 1997; 3:23-36.
12. Tang J, Shelton B, Makhatadze NJ, et al. Distribution of chemokine receptor CCR2 and CCR5 genotypes and their relative contribution to human immunodeficiency virus type 1 (HIV-1) seroconversion, early HIV-1 RNA concentration in plasma, and later disease progression. J Virol 2002; 76:662-672.
13. Trecarichi EM, Tumbarello M, de Gaetano Donati K, et al. Partial protective effect of CCR5-delta 32 heterozygosity in a cohort of heterosexual Italian HIV-1 exposed uninfected individuals. AIDS Res Ther 2006; 3:22.
14. Saez-Cirion A, Versmisse P, Truong LX, et al. Persistent resistance to HIV-1 infection in CD4 T cells from exposed uninfected Vietnamese individuals is mediated by entry and post-entry blocks. Retrovirology 2006; 3:81. (Pubitemid 44774198)
15. + patients. J Immunol 2005; 174:5655-5664.
16. Gonzalez E, Kulkarni H, Bolivar H, et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 2005; 307:1434-1440.
17. Lederman MM, Offord RE, Hartley O. Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nat Rev Immunol 2006; 6:371-382.
18. Quinones-Mateu ME, Lederman MM, Feng Z, et al. Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. AIDS 2003; 17:F39-F48.
19. Hollox EJ, Armour JA, Barber JC. Extensive normal copy number variation of a beta-defensin antimicrobial-gene cluster. Am J Hum Genet 2003; 73:591-600.
20. Pichlmair A, Reis e Sousa C. Innate recognition of viruses. Immunity 2007; 27:370-383.
21. Der SD, Zhou A, Williams BR, Silverman RH. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A 1998; 95:15623-15628.
22. Abel K, Rocke DM, Chohan B, Fritts L, Miller CJ. Temporal and anatomic relationship between virus replication and cytokine gene expression after vaginal simian immunodeficiency virus infection. J Virol 2005; 79:12164-12172.
23. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
24. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461:798-801.
25. Malim MH. APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos Trans R Soc Lond B Biol Sci 2009; 364:675-687.
26. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008; 451:425-430.
27. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 2004; 427:848-853.
28. Stremlau M, PerronM,Welikala S, Sodroski J. Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction. J Virol 2005; 79:3139-3145.
29. Sewram S, Singh R, Kormuth E, et al. Human TRIM5alpha expression levels and reduced susceptibility to HIV-1 infection. J Infect Dis 2009; 199:1657-1663.
30. Valcke HS, Bernard NF, Bruneau J, Alary M, Tsoukas CM, Roger M. APOBEC3G genetic variants and their association with risk of HIV infection in highly exposed Caucasians. AIDS 2006; 20:1984-1986.
31. Brass AL, Dykxhoorn DM, Benita Y, et al. Identification of host proteins required for HIV infection through a functional genomic screen. Science 2008; 319:921-926.
32. Schwartz O, Marechal V, Le Gall S, Lemonnier F, Heard JM. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med 1996; 2:338-342.
33. Martin MP, Gao X, Lee JH, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002; 31:429-434.
34. Ravet S, Scott-Algara D, Bonnet E, et al. Distinctive NK-cell receptor repertoires sustain high-level constitutive NK-cell activation in HIV-exposed uninfected individuals. Blood 2007; 109:4296-4305.
35. Scott-Algara D, Truong LX, Versmisse P, et al. Cutting edge: increased NK cell activity in HIV-1-exposed but uninfected Vietnamese intravascular drug users. J Immunol 2003; 171:5663-5667.
36. Bernard NF, Yannakis CM, Lee JS, Tsoukas CM. Human immunodeficiency virus (HIV)-specific cytotoxic T lymphocyte activity in HIV-exposed seronegative persons. J Infect Dis 1999; 179:538-547.
37. Fowke KR, Dong T, Rowland-Jones SL, et al. HIV type 1 resistance in Kenyan sex workers is not associated with altered cellular susceptibility to HIV type 1 infection or enhanced beta-chemokine production. AIDS Res Hum Retroviruses 1998; 14:1521-1530.
38. Goh WC, Markee J, Akridge RE, et al. Protection against human immunodeficiency virus type 1 infection in persons with repeated exposure: evidence for T cell immunity in the absence of inherited CCR5 coreceptor defects. J Infect Dis 1999; 179:548-557.
39. Wasik TJ, Bratosiewicz J, Wierzbicki A, et al. Protective role of beta-chemokines associated with HIV-specific Th responses against perinatal HIV transmission. J Immunol 1999; 162:4355-4364.
40. Buge SL, Murty L, Arora K, et al. Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251. J Virol 1999; 73:7430-7440.
41. Sun Y, Bailer RT, Rao SS, et al. Systemic and mucosal T-lymphocyte activation induced by recombinant adenovirus vaccines in rhesus monkeys. J Virol 2009; 83:10596-10604.
42. Zhao J, Pinczewski J, Gomez-Roman VR, et al. Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen. J Virol 2003; 77:8354-8365.
43. Kaul R, Trabattoni D, Bwayo JJ, et al. HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. AIDS 1999; 13:23-29.
44. Galvin SR, Cohen MS. The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol 2004; 2:33-42.
45. Sewankambo N, Gray RH, Wawer MJ, et al. HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis. Lancet 1997; 350:546-550. (Pubitemid 27348430)
46. Lisco A, Vanpouille C, Margolis L. War and peace between microbes: HIV-1 interactions with coinfecting viruses. Cell Host Microbe 2009; 6:403-408.
47. Menitove JE, Aster RH, Casper JT, et al. T-lymphocyte subpopulations in patients with classic hemophilia treated with cryoprecipitate and lyophilized concentrates. N Engl J Med 1983; 308:83-86.
48. Lederman MM, Ratnoff OD, Evatt BL, McDougal JS. Acquisition of antibody to lymphadenopathy-associated virus in patients with classic hemophilia (factor VIII deficiency). Ann Intern Med 1985; 102:753-757.
49. Kroner BL, Rosenberg PS, Aledort LM, Alvord WG, Goedert JJ. HIV-1 infection incidence among persons with hemophilia in the United States and Western Europe, 1978-1990: Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 1994; 7:279-286.
50. Salkowitz JR, Purvis SF, Meyerson H, et al. Characterization of high-risk HIV-1 seronegative hemophiliacs. Clin Immunol 2001; 98:200-211.
51. + T cell activation is associated with low susceptibility to HIV-1 infection. J Immunol 2005; 175:6117-1122.
52. + regulatory T cells. J Infect Dis 2009; 199:1318-1322.
53. Li Q, Estes JD, Schlievert PM, et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature 2009; 458:1034-1038.
54. + T cells. Nature 2005; 435:108-114.